Please assess the completion status of the following clinical trial:

Trial Title: In Vivo and in Vitro Efficacy of Antimalarial Treatments in Children in Burkina Faso

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 6 - 59 months~* Weight \> 5 kg~* Mono-infection with P. falciparum~* Parasitemia of 4,000-200,000 asexual parasites per µl~* Fever: \> 37.5 °C or history of fever in the preceding 24 hours~* Haemoglobin \> 5.0 g/dl~* Signed informed consent by the parents or guardians~* Parents' or guardians' willingness and ability to comply with the study protocol for the duration of the trial.~Exclusion Criteria:~* Participation in any other clinical trial during the previous 30 days~* Known hypersensitivity to the study drugs~* Severe and/or complicated malaria (cases will be referred to Bobo-Dioulasso University hospital for treatment)~* Danger signs: not able to drink or breast-feed, vomiting (\> twice in 24hours), recent history of convulsions (\>1 in 24h), unconscious state, unable to sit or stand;~* Known intercurrent illness or any condition which would place the subject at undue risk or interfere with the results of the study.~* Severe malnutrition (weight for height \<70% of the median NCHS/WHO reference)

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- Artemether -lumefantrine (Type: EXPERIMENTAL): Treatment of malaria with Artemether-lumefantrine (AL), according to one of the two options given by national protocol in Burkina Faso
- Artesunate-amodiaquine (Type: EXPERIMENTAL): Treatment of malaria with Artesunate-amodiaquine(AS-AQ), according to one of the two options given by national protocol in Burkina Faso

Based on this trial design, predict the completion outcome and termination type (if applicable).